LOGIN 
23 December 2022
In China, price negotiations are mandatory for originator drugs to be listed on the National Reimbursement Drug List (NRDL), however, the process to determine a reimbursement price is not transparent. In practice, there are a number of drivers influencing the envelope price put forward by the National Healthcare Security Administration (NHSA) at the negotiation stage. Overlooking these key drivers of price might lead to an unsuccessful NRDL outcome.
Objectives
The aim of this study was to:
The objective of this study is to explore the key drivers of the envelope price at the negotiation stage of the NRDL process for originators seeking an NRDL listing.
Download the full report: